Conclusion: sleep efficiency was reduced by an average of 5% in 2/3 of the nights following IFNβ injections compared to the other nights, and daily sleep ratings correlated with actigraphy. Patients on glatiramer acetate also showed a lower sleep efficiency than patients without therapy. Actigraphy data were only modestly correlated with MOSsm scores, not with fatigue. Long term adaptation of sleep effects of immunomodulant agents is incomplete and needs to be considered in treatment planning and assessment of sleep in MS. (Source: Multiple Sclerosis)
Posted: 2010-02-08 06:48:12
More from this author:
Multiple Sclerosis: What Part Do Relapses Play In Severe Disability?
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Multiple Sclerosis Relapses and Severe Disability
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis.
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Stress, Fear, Anxiety and MS
From the Web > About.com Multiple Sclerosis: Most Popular Article
From the Web > About.com Multiple Sclerosis: Most Popular Article
Puusepp's sign—Clinical significance of a forgotten pyramidal sign
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Related Articles:
